

Insulin-like Growth Factor Binding Protein-2 ELISA E05/E08 – human or mouse / rat

Insulin-like growth factors (IGF)-I and -II are bound to specific binding proteins (IGFBPs) in the circulation. Today the existence of at least seven binding proteins and several related proteins has been shown. The second most frequent IGFBP in blood is IGFBP-2. IGFs, especially tumor typical pro-IGFforms and hormones regulate the expression of IGFBP-2. At cellular level IGFBP-2 seems to stimulate the proliferation and dissemination of solid tumors via an **IGF-independent** mechanism



Reference values of human serum IGFBP-2

IGFBP-2 is a non-glycosylated polypeptide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation. The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission.

During the GH-therapy, e.g. in short stature and in GH-abuse (doping) the IGFBP-2 level decreases. In Trisomy 18 IGFBP-2 in maternal serum is decreased and IGFBP-1 is increased; therefore the ratio IGFBP-2 /IGFBP-1 is a marker for this chromosome abnormality. Low IGFBP-2 serum levels were found to be in a study as a significant indicator for good physical-functional condition of senior men (positive: muscle power or bone density; negative: adipose mass)

We offer two IGFBP-2 assay systems, one for measurement of IGFBP-2 in human body fluids and one for IGFBP-2 determination **in mouse/rat serum**. The rodent IGFBP-2 assay contains murine IGFBP-2 for calibration but by measurement of recombinant rat IGFBP-2 cross-reactivity has been proven.

Mediagnost HUMAN-IGFBP-2 E05

Based on highly specific polyclonal and monoclonal antibodies. Mediagnost E05 allows quantitative determination of IGFBP-2 in human **serum**, **plasma**, **amnion and cerebrospinal fluid** as well as in cell culture supernatants. IGFBP-2 in serum is stable; sample can be taken any time of the day and stored frozen until usage. Recombinant IGFBP-2 was used for calibration. **400 reference values** measured in humans of a broad range of age are available.

No cross reactivity to other components of the IGF system are known. And small sample requirement is **ideal for use in paediatrics**.

Mediagnost IGFBP-2 ELISA has an **European Approval for Clinical Diagnostics**:EC Directive 98/79EG (**C**).

Assay Features HUMAN-IGFBP-2 E05

- Theoretical sensitivity of 0.2 ng/mL
- ✓ Single Standards: 2, 10, 20, 40, 80 ng/mL, human IGFBP-2
- ✓ Intra- and Interassay variance ≤ 10%
- ✓ 2 internal control sera: RiliBÄK conform
- ✓ Recovery in serum 97-115%

Mediagnost MOUSE- / RAT-IGFBP-2 E08

For research purposes we offer a Mouse- / Rat-IGFBP-2 ELISA. Highly sensitive monoclonal antibodies allow detection of IGFBP-2 in very small samples (**2.5 µL for duplicates**).

- ✓ Detection limit of 0.01 ng/mL
- Standards: 31.25 2000 pg/mL recombinant mouse IGFBP-2
- ✓ Intra- and Interassay variance <10%
- Control serum included
- ✓ Linearity shown for 1:100 1:320 dilution

HUMAN-IGFBP-2 ELISA E05

Preparation of reagents:			Reconstitution:	Dilution:		
Before assay procedure bring all reagents to room temperature 20-25°C.						
A-E Standards ir			in 750 µL Dilution Buffer VP	-		
KS1	Control Serum 1		in 100 µL Dilution Buffer VP	1:21 with Dilution Buffer VP		
KS2	2 Control Serum 2		in 100 µL Dilution Buffer VP	1:21 with Dilution Buffer VP		
WP	NP Washing Buffer		-	1:20 with Aqua dest.		
Sample dilution: with Dilution Buffer VP 1:21						
Assay	Assay Procedure in Double Determination:					
Pipettie F		R	Reagents		Position	
100 µL Di		Dilution Buffer VP (Blank)		A1/A2		
100 µL 🕴		Standard A (2 ng/mL)	ndard A (2 ng/mL)		B1/B2	
100 µL		Standard B (10 ng/mL)		C1/C2		
100 µL		Standard C (20 ng/mL)		D1/D2		
100 µL Standa		Standard D (40 ng/mL)	tandard D (40 ng/mL)		E1/E2	
100 µL		Standard E (80 ng/mL)		F1/F2		
100 µL		Control Serum	(1:21 diluted)	G1/A2		
100 µL		Control Serum	(1:21 diluted)	A3/A4		
100 µL Sample		Sample	(1:21 diluted)	in the rest of the wells according the requirements		
Cover the wells with the sealing tape.						
Sample incubation: 1 h at 20-25°C, 350 rpm						
5X 300 µL Aspirate the contents o		Aspirate the contents of	the wells and wash 5 x with 300 µL each Was	Sning Buffer VVP/ Well. In each Well		
100 µL Antibody Conjugate Ar In each well					in each well	
Cover the wells with the sealing tape.						
Incubation: 30 min at 20-25°C, 350 rpm						
5x 300 µL Aspirate the contents of		Aspirate the contents of	of the wells and wash 5 x with 300 μL each Washing Buffer WP/ well.		In each well	
100 μL Substrate Solution S		Substrate Solution S			In each well	
Substrat S Incubation: 15 min in the Dark at 20-25°C						
100 μL Stopping Solution SL		Stopping Solution SL	In jede Ver		In jede Vertiefung	
	Measure the absorbance within 30 min at 450 nm with ≥ 590 nm as reference wavelength.					
Mouse/Rat-IGFBP-2 ELISA E08						
Preparation of reagents: Reconstitution: Dilution:						
Before assay procedure bring all reagents to room temperature 20-25°C.						
A-G Standards		s	in 1 mL Dilution Buffer VP			
KS	Control S	Serum in 250 µL Dilution Buffer VP 1:100 with Dilu		1:100 with Dilution Buf	on Buffer VP	
AK	Antbody	Conjugate	-	1:100 with Dilution Buffer VP		
EK	Enzyme (Conjugate	-	1:100 with Dilution Buffer VP		
WP	Washing	Buffer	-	1:20 with Aqua dest.		
Sample dilution: with Dilution Buffer VP 1:100						
Assay Procedure in Double Determination:						
Pipettie		R	leagents	Position		
100 µL		Dilution Buffer VP (Blan	k)	A1/A2		
100 µL		Standard A (31.25 pg/n	d A (31.25 pg/mL) B1/B2		B1/B2	
100 µL		Standard B (62.5 pg/m)	L)	C1/C2		
100 μL		Standard C (125 pg/mL)		D1/D2		
100 µL		Standard D (250 pg/mL)		E 1/E2		
100 µL 3		Standard E (300 pg/mL)				
100 µL S				61/62		
100 µL 100 µI						
100 μL 0		Control Serum	(1:100 diluted)	A3/A4		
Cover the wells with the sealing tape.						
Sample Incubation: 1 h at 20-25°C, 350 rpm						
5x 300 µL Aspirate the contents of the wells and wash 5 x with 300 µL each Washing Buffer WE				shing Buffer WP/ well	In each well	
100 μL		Antibody Conjugate AK (1:100 diluted)			In each well	
Cover	the wells w	vith the sealing tape.	· ·			
Incubation: 1 h at 20-25°C, 350 rpm						
5x 300	uL	Aspirate the contents of	contents of the wells and wash 5 x with 300 uL each Washing Buffer WP/ well		In each well	
100 ul	··-	Enzyme Conjugate EK (1:100 diluted)			In each well	
Cover the wells with the sealing tape.						
Incubation: 0.5 h at 20-25°C, 350 rpm						
5x 300 µL		Aspirate the contents of	Aspirate the contents of the wells and wash 5 x with 300 µL each Washing Buffer WP/ well. In each well			
100 µL		Substrate Solution S			In each well	
Substr	at S Incub	pation: 0.5 h in the Dark	c at 20-25°C			
100 µL Stopping Solution SL In iede Vertiefung						
Measure the absorbance within 30 min at 450 nm with ≥ 590 nm as reference wavelength.						

Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Aspenhaustr 25 72770 Reutlingen Deutschland +49 7121 51 4840 - www.mediagnost.de - contact@mediagnost.de